CEL-SCI (CVM) Competitors $9.20 -0.11 (-1.18%) As of 09:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVM vs. VOR, IMMP, SCPH, ALEC, TKNO, ANNX, EDIT, HUMA, SOPH, and FENCShould you be buying CEL-SCI stock or one of its competitors? The main competitors of CEL-SCI include Vor Biopharma (VOR), Prima BioMed (IMMP), scPharmaceuticals (SCPH), Alector (ALEC), Alpha Teknova (TKNO), Annexon (ANNX), Editas Medicine (EDIT), Humacyte (HUMA), SOPHiA GENETICS (SOPH), and Adherex Technologies (FENC). These companies are all part of the "pharmaceutical products" industry. CEL-SCI vs. Its Competitors Vor Biopharma Prima BioMed scPharmaceuticals Alector Alpha Teknova Annexon Editas Medicine Humacyte SOPHiA GENETICS Adherex Technologies CEL-SCI (NYSE:CVM) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Do institutionals and insiders hold more shares of CVM or VOR? 12.1% of CEL-SCI shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 9.9% of CEL-SCI shares are held by insiders. Comparatively, 0.5% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, CVM or VOR? CEL-SCI has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Does the media prefer CVM or VOR? In the previous week, Vor Biopharma had 3 more articles in the media than CEL-SCI. MarketBeat recorded 8 mentions for Vor Biopharma and 5 mentions for CEL-SCI. CEL-SCI's average media sentiment score of 0.00 beat Vor Biopharma's score of -0.06 indicating that CEL-SCI is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CEL-SCI 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vor Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer CVM or VOR? Vor Biopharma has a consensus price target of $6.07, suggesting a potential upside of 201.82%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than CEL-SCI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CEL-SCI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vor Biopharma 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56 Which has higher valuation & earnings, CVM or VOR? CEL-SCI is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCEL-SCIN/AN/A-$26.92M-$9.77-0.95Vor BiopharmaN/AN/AN/A-$13.66-0.15 Is CVM or VOR more profitable? Vor Biopharma's return on equity of 0.00% beat CEL-SCI's return on equity.Company Net Margins Return on Equity Return on Assets CEL-SCIN/A -238.05% -104.65% Vor Biopharma N/A N/A N/A SummaryVor Biopharma beats CEL-SCI on 9 of the 12 factors compared between the two stocks. Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVM vs. The Competition Export to ExcelMetricCEL-SCIBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$89.74M$283.56M$5.77B$21.29BDividend YieldN/AN/A3.95%3.51%P/E Ratio-19.40N/A31.2729.34Price / SalesN/A538.68440.2650.79Price / CashN/A22.4437.7323.86Price / Book62.0710.1710.615.39Net Income-$26.92M-$115.81M$3.27B$996.59M7 Day Performance-2.21%0.04%1.41%0.41%1 Month Performance30.21%0.41%6.20%3.49%1 Year Performance-71.40%-14.82%50.13%12.09% CEL-SCI Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVMCEL-SCI0.526 of 5 stars$9.11-2.1%N/A-71.4%$64.06MN/A-19.3943News CoverageGap DownVORVor Biopharma1.9503 of 5 stars$2.06-5.1%$6.07+194.5%+133.7%$260.97MN/A-1.25140Insider TradeIMMPPrima BioMed1.5277 of 5 stars$1.70-4.0%$7.00+311.8%-33.9%$259.81M$5.14M0.002,021Positive NewsSCPHscPharmaceuticals4.1892 of 5 stars$5.52+13.8%$14.00+153.6%+12.0%$258.50M$36.33M-3.0530High Trading VolumeALECAlector3.997 of 5 stars$2.34-7.1%$4.17+78.1%-54.1%$255.05M$81.13M-2.02270News CoverageTKNOAlpha Teknova2.4306 of 5 stars$4.48-5.7%$10.00+123.2%-7.7%$254.20M$37.74M-10.67240Positive NewsANNXAnnexon2.4056 of 5 stars$2.15-6.9%$12.50+481.4%-64.3%$253.84MN/A-1.6760EDITEditas Medicine4.2489 of 5 stars$2.72-2.9%$5.10+87.5%-28.0%$251.78M$32.31M-0.95230HUMAHumacyte2.5524 of 5 stars$1.50-5.1%$10.64+609.5%-75.5%$250.23M$1.57M-3.33150Positive NewsAnalyst ForecastGap UpSOPHSOPHiA GENETICS2.7415 of 5 stars$3.45-4.4%$8.00+131.9%-12.9%$243.96M$65.17M-7.84520FENCAdherex Technologies2.1064 of 5 stars$8.65-0.1%$13.33+54.1%+63.1%$240.87M$47.54M-20.5910 Related Companies and Tools Related Companies Vor Biopharma Competitors Prima BioMed Competitors scPharmaceuticals Competitors Alector Competitors Alpha Teknova Competitors Annexon Competitors Editas Medicine Competitors Humacyte Competitors SOPHiA GENETICS Competitors Adherex Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CVM) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access